[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"flushing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:flushing":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638035","transcutaneous-auricular-vagus-nerve-stimulation-treatment-for-rosacea-100638035",false,"NCT07600424","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea: A Pilot Trial","Inclusion Criteria:\n\n* Adults aged 18 years of age and older\n* Dermatologist confirmed diagnosis of rosacea\n* Clinician's Erythema Assessment of at least 3 (moderate to severe disease)\n* Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.\n\nExclusion Criteria:\n\n* Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.\n* Facial hair, tattoos, or other characteristics that would interfere with erythema assessments\n* History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)\n* Presence of a pacemaker, implanted defibrillator, or neurostimulator\n* Seizure disorder or epilepsy\n* Trigeminal Neuralgia within the past year\n* Severe coronary disease or recent myocardial infarction within the past 5 years\n* Severe autonomic dysfunction (e.g., frequent syncope, hospitalization)\n* History of recurrent syncope or unexplained fainting\n* Use of brimonidine or oxymetazoline within the past 4 weeks\n* Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks\n* Severe phymatous rosacea\n* Ear deformity, piercings, or other condition that prevents the use of the taVNS device\n* Known hypersensitivity to electrode materials\n* Patients who are pregnant.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results",[26,27,28],"Rosacea","Rosacea, Erythematotelangiectatic","Flushing","NOT_YET_RECRUITING","2026-05-20",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":20},"2026-06-01",{"date":37,"type":20},"2028-02-28",{"name":39,"class":40},"Brigham and Women's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100623141","aldh2-genetic-testing-in-east-asian-community-100623141","NCT07392775","ALDH2 Genetic Testing in East Asian Community","A Community-Based Approach for ALDH2 Genetic Testing in East Asian Americans","Inclusion Criteria:\n\n1. Age 18 or older\n2. Self-identified as East Asian and\u002For East Asian American\n3. Flush when they drink alcohol or have a family member who flushes when they drink\n4. Able to read and speak English",true,{"count":51,"type":20},100,[23],"The goal of this clinical trial is to learn whether education plus genetic testing for ALDH2\\*2 and ADH1B\\*2 is feasible and acceptable and whether it influences modifiable health behaviors in East Asian American adults who experience alcohol flushing when they drink alcohol or have a family history of flushing. The main questions it aims to answer are:\n\n1. Is providing education plus ALDH2\\*2\u002FADH1B\\*2 genetic testing feasible and acceptable in a clinical care context?\n2. Does receiving genetic testing results plus education lead to changes in modifiable health behaviors compared with education alone? Researchers will compare education plus genetic testing (intervention arm) to education only (control arm) to see if adding genetic testing improves feasibility\u002Facceptability and supports health behavior change.\n\nParticipants will:\n\n1. Complete an education module about alcohol flushing and ALDH2\u002FADH1B\n2. Be randomized to either: (A) Receive genetic testing for ALDH2\\*2 and ADH1B\\*2 with results disclosure, or (B) Receive education only.\n3. Complete follow-up measures about feasibility, acceptability, and modifiable health behaviors",[55,28],"Healthy Adult",[57,58,59,60,61,62,63,64],"East Asian","Alcohol Flushing","ALDH2","ADH1B","Esophageal Cancer","Genetic Testing","Alzheimer's Disease","Cardiovascular Disease","2026-02-04",{"date":67,"type":33},"2026-02-06",{"date":69,"type":20},"2026-09-01",{"date":71,"type":20},"2029-06-30",{"name":73,"class":40},"Northwestern University"]